CAR T-cell therapy for B-cell lymphoma.

Area of Science:

• Hematology
• Immunotherapy
• Oncology

Background:

• Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 has transformed B-cell lymphoma treatment.
• FDA-approved anti-CD19 CAR T-cell therapies are now standard for relapsed/refractory aggressive non-Hodgkin's Lymphoma (NHL).

Purpose of the Study:

• This review examines FDA-approved anti-CD19 CAR T-cell products for indolent and aggressive B-cell lymphomas.
• It also discusses CAR T-cell therapy failure mechanisms and potential future strategies.

Main Methods:

• Review of current literature on anti-CD19 CAR T-cell therapy in B-cell lymphomas.
• Analysis of FDA-approved products: axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel.

Main Results:

• Anti-CD19 CAR T-cell therapy demonstrates high response rates and durability in B-cell lymphomas.
• Real-world data confirm the feasibility of CAR T-cell therapy for a wide patient population.

Conclusions:

• CAR T-cell therapy is a crucial advancement in B-cell lymphoma treatment.
• Investigating mechanisms of failure and developing strategies to address them are essential for improving patient outcomes.